Protagonist Therapeutics, Inc (PTGX) Operating margin 2017–2025
Protagonist Therapeutics, Inc (PTGX) operating margin by fiscal year — reported operating income divided by reported revenue.
-343.6%FY2025 · since FY2017: -188.9% → -343.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -343.6% | -401.8 pp |
| FY2024 | 58.2% | +214.3 pp |
| FY2023 | -156.1% | +338.1 pp |
| FY2022 | -494.2% | -34.2 pp |
| FY2021 | -460.0% | -234.7 pp |
| FY2020 | -225.4% | +34632.2 pp |
| FY2019 | -34857.6% | -34720.9 pp |
| FY2018 | -136.7% | +52.2 pp |
| FY2017 | -188.9% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX RevenuePTGX Net incomePTGX Net marginPTGX Gross profitPTGX Gross marginPTGX Operating incomePTGX Operating cash flowPTGX Free cash flowPTGX Capital expendituresPTGX Return on equityPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Total liabilitiesPTGX Shareholders’ equityPTGX overview →